DYN
Dyne Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +5.9% ·
share flow +28.2% ·
net new positions 0.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 86 | +1 | 73.73M | $1.63B | +7 | −5 |
| Q1 2026 | 87 | -4 | 78.51M | $1.42B | +7 | −12 |
| Q4 2025 | 92 | 0 | 87.58M | $1.71B | +2 | −1 |
| Q3 2025 | 18 | +1 | 57.06M | $721.88M | +1 | −1 |
| Q2 2025 | 15 | +2 | 34.50M | $328.45M | +2 | n/a |
| Q1 2025 | 10 | -1 | 12.46M | $130.33M | +1 | −2 |
| Q4 2024 | 11 | 0 | 14.93M | $351.71M | +1 | −1 |
| Q3 2024 | 10 | -2 | 10.58M | $380.14M | +1 | −3 |
| Q2 2024 | 12 | n/a | 13.13M | $463.42M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 9.76M | +27.6% | $123.47M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 9.63M | +19.3% | $121.88M | 0.0% | ▲ Add | 2 | SEC ↗ ×15 |
| 3 | JPMorgan Chase ✦ | 6.73M | n/a | $85.14M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 4 | Fidelity (FMR) ✦ | 5.40M | +2.0% | $68.33M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 5 | State Street Global Advisors ✦ (passive) | 5.27M | +57.0% | $66.65M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Adage Capital Partners ✦ | 3.55M | +11.4% | $44.96M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 3.41M | +261.6% | $43.18M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Marshall Wace ✦ | 3.01M | +572.9% | $38.12M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 2.87M | +27.2% | $36.28M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Goldman Sachs Group ✦ | 1.90M | n/a | $24.04M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | Point72 Asset Management ✦ | 1.72M | +1293.4% | $21.73M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 12 | Morgan Stanley ✦ | 1.42M | n/a | $17.95M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 13 | T. Rowe Price ✦ | 1.40M | -41.4% | $17.69M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 14 | Millennium Management ✦ | 413.94K | +190.0% | $5.24M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 345.50K | New | $4.37M | 0.0% | New | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 141.88K | +230.6% | $1.79M | 0.0% | ▲ Add | 3 | SEC ↗ ×5 |
| 17 | Wellington Management ✦ | 41.91K | +23.2% | $530,224 | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 18 | D. E. Shaw & Co. ✦ | 41.59K | -91.8% | $526,076 | 0.0% | ▼ Trim | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $4.37M | 0.0% |
Exited
| Norges Bank | $469,517 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 226 holders, 184.59M shares, $2.74B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 2.50K sh @ 16.00 · $40,000
Open-market sales (S)
Officer, Director · 5.66K sh · $106,823
Officer · 1.29K sh · $24,355
Officer · 185 sh · $3,493
Officer · 3.75K sh · $91,191
Officer · 900 sh · $21,915
Director · 478.38K sh · $11.96M
Director · 1.36M sh · $33.99M
Director · 322.46K sh · $8.06M
Officer · 1.56K sh · $40,892
Director · 268.35K sh · $7.03M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology